Livzon Pharmaceutical Group

Livzon Pharmaceutical Group, located in Zhuhai City, China, has enjoyed rapid growth since its founding in 1985. As the first public company in that nation's pharmaceutical industry, Livzon made its initial public offering in 1993. In 1995, with sales of 140 million U.S. dollars, the company ranked second among China's top 50 pharmaceutical firms.

Livzon employs 1,700 employees on a campus of 37 acres, with a modern manufacturing plant of 860,000 square feet. In additon, It has the most prestigious and advanced facilities for product research and development. Further, It has formed a number of joint research programs with major research institutes and universities. Research, manufacture and sales have been linked into an integrated system to transform research discoveries into commercial products. The company has also formed a research center for the modernization of traditional Chinese medicine.

The Group has 11 domestic subsidiaries, 6 joint ventures, and 3 worldwide enterprises. The products it currently manufactures cover the areas of biotechnological, biochemical, synthetic pharmaceutical compounds, antibiotic, microbiological, herbal products, nutritional supplements, testing kits, biological materials, and medical electronic products including therapeutic categories of gastrointestinal, cardiovascular, respiratory, anti- cancer and other important areas of health and well-being.

The Group has approximately 800 sales specialists located at 74 sales offices nationwide, a network covering all of the country's geographical areas.The Group distributes not only hundreds of pharmaceutical products of its own manufacture but also products made by foreign companies,the sales of imported products comprise 10 percent of the nation's total imported pharmaceutical market. Through the successful distribution of these imported products in China, Livzon Pharmaceutical Group has earned an enviable reputation worldwide.

Livzon Pharmaceutical Group provides the following services in China to foreign firms:

Back